—

Crinetics Pharmaceuticals Inc (CRNX) — the peer cohort

As of 2026-11-16 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Crinetics Pharmaceuticals Inc ranks 7 of 7 in its cohort on the Closelooknet composite (50/100) — the cohort is led by Halozyme Therapeutics Inc at 72/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
CRNX Crinetics Pharmaceuticals Inc 50 99 21 5 — —
HALO Halozyme Therapeutics Inc 72 68 94 49 info 28%
ARGX.BR Argen-X 64 79 75 25 ok 5.1%
UCB.BR UCB SA 64 75 70 42 info 2%
ARGX argenx NV ADR 63 70 74 25 ok 11.4%
PTGX Protagonist Therapeutics Inc 61 64 72 18 info 22.4%
BION.SW BB Biotech AG 60 74 95 71 ok 5.1%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-11-16

Quick answers

Who are Crinetics Pharmaceuticals Inc's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), Argen-X (ARGX.BR), UCB SA (UCB.BR), argenx NV ADR (ARGX), Protagonist Therapeutics Inc (PTGX), BB Biotech AG (BION.SW), as of 2026-11-16.

How does CRNX score against its peers?

Crinetics Pharmaceuticals Inc's composite reads 50/100, ranking 7 of 7 in its cohort as of 2026-11-16; the cohort's highest composite is Halozyme Therapeutics Inc at 72/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.